Racura Oncology (ASX:RAC) Asset Impairment Charge: A$0.00 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RAC Racura Oncology Ltd ASX:RAC
16 GF Score
Price A$2.10
! 1 Warning Sign
View Full Analysis

What is Racura Oncology Asset Impairment Charge?

Racura Oncology ASX:RAC -1.87% 16 Asset Impairment Charge is A$0.00 Mil as of Jun. 2026. GuruFocus rates ASX:RAC with a GF Score™ of 16/100. The stock has 1 warning sign investors should review.

Racura Oncology's Asset Impairment Charge for the six months ended in Jun. 2026 was A$0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.00 Mil.

Racura Oncology Asset Impairment Charge Related Terms

Racura Oncology Asset Impairment Charge Historical Data

* Premium members only.

The historical data trend for Racura Oncology's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Racura Oncology Asset Impairment Charge Chart

Racura Oncology Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Asset Impairment Charge
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Racura Oncology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Asset Impairment Charge Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:RAC
16GF Score
Racura Oncology Ltd ASX:RAC
Asset Impairment Charge is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Racura Oncology Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

What does a Asset Impairment Charge of A$0.00 Mil mean?
Racura Oncology (ASX:RAC) has a Asset Impairment Charge of A$0.00 Mil as of Jun. 2026.
Is Racura Oncology's Asset Impairment Charge too high?
Racura Oncology's current Asset Impairment Charge is A$0.00 Mil. Overall, Racura Oncology has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's Asset Impairment Charge compare to VRTX and REGN?
Racura Oncology's Asset Impairment Charge of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Impairment Charge for a Biotechnology company?
A good Asset Impairment Charge depends on the Biotechnology industry context. However, Asset Impairment Charge should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Impairment Charge mean?
A high Asset Impairment Charge can signal that a stock is expensive relative to its fundamentals. Racura Oncology's current Asset Impairment Charge is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current Asset Impairment Charge of A$0.00 Mil. The current Asset Impairment Charge is A$0.00 Mil. Racura Oncology's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Impairment Charge calculated?
Asset Impairment Charge is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current Asset Impairment Charge is A$0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
16GF Score

Get the complete analysis for ASX:RAC

Asset Impairment Charge is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.10
Price